As of 2025-07-11, the Intrinsic Value of Pharmsville Co Ltd (318010.KQ) is 2,379.03 KRW. This 318010.KQ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 3,920.00 KRW, the upside of Pharmsville Co Ltd is -39.30%.
The range of the Intrinsic Value is 1,833.61 - 3,699.80 KRW
Based on its market price of 3,920.00 KRW and our intrinsic valuation, Pharmsville Co Ltd (318010.KQ) is overvalued by 39.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1,833.61 - 3,699.80 | 2,379.03 | -39.3% |
| DCF (Growth 10y) | 2,277.00 - 4,505.75 | 2,932.80 | -25.2% |
| DCF (EBITDA 5y) | 1,894.81 - 3,639.13 | 2,611.41 | -33.4% |
| DCF (EBITDA 10y) | 2,233.99 - 4,152.34 | 3,003.39 | -23.4% |
| Fair Value | 1,173.23 - 1,173.23 | 1,173.23 | -70.07% |
| P/E | 2,591.32 - 4,406.65 | 3,408.56 | -13.0% |
| EV/EBITDA | 1,295.38 - 3,370.34 | 1,940.77 | -50.5% |
| EPV | 1,956.42 - 2,394.40 | 2,175.41 | -44.5% |
| DDM - Stable | 2,528.95 - 7,887.95 | 5,208.45 | 32.9% |
| DDM - Multi | 2,548.74 - 6,189.09 | 3,611.83 | -7.9% |
| Market Cap (mil) | 31,085.60 |
| Beta | 0.48 |
| Outstanding shares (mil) | 7.93 |
| Enterprise Value (mil) | 28,333.10 |
| Market risk premium | 5.82% |
| Cost of Equity | 7.59% |
| Cost of Debt | 4.25% |
| WACC | 7.58% |